Abbott Laboratories

NYSE:ABT   3:59:59 PM EDT
+0.82 (+0.73%)

Abbott Laboratories Says Subject To FDA Approval, Could Restart Sturgis, Mich., Site Within Two Weeks

Published: 05/11/2022 18:26 GMT
Abbott Laboratories (ABT) - Abbott Laboratories - Subject to FDA Approval, We Could Restart Our Sturgis, Mich.
, Site Within Two Weeks.
Abbott Laboratories - Would Begin Production of Elecare, Alimentum & Metabolic Formulas First and Then Begin Production of Similac and Other Formulas.
Abbott Laboratories - .
From the Time We Restart the Site, It Will Take Six to Eight Weeks Before Product is Available on Shelves.
Abbott Laboratories - After a Thorough Review of All Available Data, There is No Evidence to Link Our Formulas to Infant Illnesses.
Abbott Laboratories - No Abbott Formula Distributed to Consumers Tested Positive for Cronobacter Sakazakii Or Salmonella.
Abbott Laboratories - No Salmonella Was Found at the Sturgis Facility.
Further Company Coverage: Abtn ((reuters.